Cameron Price BEc, LLB (Hons) Age 60 Independent Non-executive Director Director of CSL Limited since October 2025. Costa Saroukos BCom (Acc), CIA Age 55 Independent Non-executive Director Director of CSL Limited since December 2025. Elaine Sorg BS Pharm Age 59 Independent Non-executive Director Director of CSL Limited since September 2024. Mr Price has extensive experience in global investment markets, risk management, public affairs, and legal strategy and compliance. Until mid-2025, he was General Counsel and Chief Risk Officer at the Future Fund, Australia’s Sovereign Wealth Fund, which manages the global investment of more than $330 billion of funds including the $260 billion Future Fund and the $25 billion Medical Research Future Fund. He held this role for 11 years. Prior to that, Mr Price was a senior commercial lawyer, partner and Board member at law firm Allens for 25 years, specialising in mergers & acquisitions, equity capital markets and corporate governance and compliance. Other directorships and offices (current and recent): • Director of Ruyton Girls’ School (since 2016). Board Committee memberships: • Chair of the Human Resources and Remuneration Committee; and • Member of the Corporate Governance and Nomination Committee. Mr Saroukos is a finance professional with over 25 years’ experience in the pharmaceutical sector. He was previously the Global Chief Financial Officer and a Board member for Takeda Pharmaceuticals, based in Tokyo. Before joining Takeda, Mr Saroukos held senior roles at Allergan Asia Ltd, including Vice President Finance Asia Pacific and Regional CFO for Greater China & Japan. Mr Saroukos also spent more than 13 years with Merck & Co, where he took on increasingly senior executive roles in Switzerland, South Korea and Australia. Mr Saroukos has extensive experience in audit, business development, financial planning and tax. He is also a member of the Australian Society of Certified Practising Accountants, the National Institute of Accountants and the American Institute of Internal Auditors. Other directorships and offices (current and recent): • Chair of the Board of Mitsubishi Tanabe Pharma (since September 2025); and • Director of Olympus Corporation (since June 2026). Board Committee memberships: • Member of the Human Resources and Remuneration Committee; and • Member of the Innovation and Development Committee. Ms Sorg has more than 35 years’ experience as a senior executive with leading pharmaceutical companies including AbbVie and Eli Lilly. Prior to her retirement in 2023, Ms Sorg was Senior Vice President for AbbVie and President of AbbVie’s US commercial operations, the company’s largest commercial business. She was a key leader in bringing a number of groundbreaking medicines to patients across immunology, oncology, neuroscience and eye care. Ms Sorg’s deep experience extends across the biopharmaceutical industry and she is recognised for her outstanding leadership and successfully building franchises and brands across therapeutic areas as well as segments. Ms Sorg holds a Bachelor of Science (Pharmacy) from Purdue University, as well as postgraduate certifications from the University of Chicago Booth School of Management and Harvard Business School. She is currently on the Dean’s Advisory Council at Purdue University School of Pharmacy and Pharmaceutical Science, and is a Senior Advisor at the Boston Consulting Group, where she advises global healthcare clients on business-critical strategies and decisions. Other directorships and offices (current and recent): • Director of Artiva Biotherapeutics, Inc. (since February 2026). Board Committee memberships: • Member of the Human Resources and Remuneration Committee; and • Member of the Innovation and Development Committee. Board of Directors 44 Governance
RkJQdWJsaXNoZXIy MjE2NDg3